Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 1998

View Archived Issues

Company Profile: FibroGen

Cantab to acquire vaccine programs for addiction from ImmuLogic

Novel enzyme inhibitors from microbial source claimed by HMR as antidiabetics

Anti-IL-5R monoclonal antibodies and antagonists in development by Tanox

More CRF antagonists emerge from Janssen/Neurocrine Biosciences collaboration

Merck obtains option to expand MDX-447 collaboration with Medarex

U.S. clinical trials of SU-6668 slated for early 1999

Peripheral nerve regeneration enhanced by hyaluronic acid in rat model

Promising phase III trial results presented for Coulter's lead cancer therapy

Biodiversity-related grant awarded to Xenova Discovery

Resveratrol shown to bind to and cleave DNA

YM-872: neuroprotective effects in animal model indicate potential in acute ischemic stroke

Cardiovascular and Renal Drugs Advisory Committee meets in late January to discuss two NDAs

Vion pursues prodrugs of 3-AP with superior biological, pharmaceutical properties

First U.S. marketing approval for Cephalon: Provigil cleared for narcolepsy-associated EDS

Acquisition broadens Isis's antisense patent estate

Phase II trial results for Immune Response's therapeutic RA vaccine published

Synvisc cleared for marketing in several Pacific Rim countries

Grant to help Faulding and collaborators develop innovative prostate cancer treatment

Ono-4057 useful in organ transplants according to results presented at Japanese congress

Effects of TAK-044 in canine model of liver ischemia-reperfusion injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...